0001209191-13-041697.txt : 20130821 0001209191-13-041697.hdr.sgml : 20130821 20130821203454 ACCESSION NUMBER: 0001209191-13-041697 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130819 FILED AS OF DATE: 20130821 DATE AS OF CHANGE: 20130821 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTIME INC CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1301 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 1301 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FARRELL STEPHEN C CENTRAL INDEX KEY: 0001188757 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 131053978 MAIL ADDRESS: STREET 1: 701 EDGEWATER DRIVE STREET 2: SUITE 360 CITY: WAKEFIELD STATE: MA ZIP: 01880 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-08-19 0 0000876343 BIOTIME INC BTX 0001188757 FARRELL STEPHEN C 13621 NW 12 STREET, SUITE 100 SUNRISE FL 33323 1 0 0 0 Common Shares, no par vaule 2013-08-19 4 P 0 1487 3.646 A 1487 D Common Shares, no par vaule 2013-08-20 4 P 0 2700 3.6585 A 4187 D Option to Purchase Common Shares 4.13 2018-06-30 Common Shares 20000 20000 D Option to Purchase Common Shares 4.12 2018-03-10 Common Shares 20000 20000 D The price of $3.646 per share represents a weighted average of prices ranging from $3.64 to $3.65 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. The price of $3.6585 per share represents a weighted average of prices ranging from $3.65 to $3.66 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2013 based upon continued service on the board of directors. Will become exercisable in four equal quarterly installments after the date of grant on May 11, 2013 based upon continued service on the board of directors. /s/ Stephen C. Farrell 2013-08-21